Life-Threatening Reaction to Lifesaving Medication: Stepwise Approach to Severe Adverse Reactions to PCSK-9 Monoclonal Antibodies

Tia Bimal; Anthony Szema; Maia Pavlovic; Dean Karalis; Eugenia Gianos

doi:10.1016/j.jaccas.2024.102614

Life-Threatening Reaction to Lifesaving Medication: Stepwise Approach to Severe Adverse Reactions to PCSK-9 Monoclonal Antibodies

JACC Case Rep. 2024 Oct 2;29(19):102614. doi: 10.1016/j.jaccas.2024.102614.

Authors

Tia Bimal¹, Anthony Szema^{2

3}, Maia Pavlovic³, Dean Karalis⁴, Eugenia Gianos^{1

3}

Affiliations

¹ Northwell, New Hyde Park, New York, Cardiovascular Institute, Lenox Hill Hospital, Northwell Health, New York, New York, USA.
² Northwell, New Hyde Park, New York, Mather Hospital, Northwell Health, Port Jefferson, New York, USA.
³ Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
⁴ Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.

Abstract

Typical side effects of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies including influenza-like illness and injection site reactions, are minor and well tolerated. This case, however, highlights a less common but severe reaction, indicating the need for clinicians to understand and manage potential rare side effects noted with biologics.

Keywords: biotechnology; cardiovascular disease; complication; hypercholesterolemia; inherited metabolic disorders; lipid metabolism disorders; pericardial effusion; pleural effusion; treatment.

Publication types

Case Reports